Apply or Avoid?  Amanta Healthcare IPO Explained in 5 Minutes

Amanta Healthcare IPO – Day 2 Oversubscribed 11.3x

The pharmaceutical sector is buzzing with excitement as the Amanta Healthcare IPO continues to attract massive investor interest. With subscription levels crossing 9 times on just the second day, this Gujarat-based sterile pharmaceuticals manufacturer has become the talk of the investment community. 

Is This IPO Right For You?

Why Investors Are Interested

• Niche Market Focus: Amanta Healthcare operates in specialised pharmaceutical segments with high barriers to entry, particularly sterile injectables and IV fluids.
• Export Growth Potential: With a presence in 21 countries and growing global demand for quality pharmaceuticals, export revenues offer significant upside.
• Advanced Manufacturing: Proprietary ABFS and SteriPort technologies provide competitive advantages and operational efficiency.
• Improving Profitability: Despite flat revenues, the 189% jump in PAT demonstrates strong operational leverage.

Concerns to Keep in Mind

• Valuation Concerns: At the upper price band, the post-issue FY25 earnings valuation stands at approximately 47x, which appears stretched.
• Revenue Pressure: The slight decline in FY25 revenues raises questions about near-term growth momentum.
• Regulatory Dependence: Pharmaceutical companies face constant regulatory scrutiny and approval requirements that can impact operations.
• Competition Intensity: The pharmaceutical sector faces intense competition from both domestic and international players.

Here’s everything investors need to know about this IPO opportunity.

Amanta Healthcare IPO Details: Price, Timeline & Structure

IPO Date	September 1, 2025 to September 3, 2025
Tentative listing Date	Sep 9, 2025
Face Value	₹10 per share
Issue Price	₹126 per share
Lot Size	119 Shares
Sale Type	Fresh Capital
Total Issue Size	Aggregating up to ₹126.00 Cr
Issue Type	Bookbuilding IPO
Listing At	BSE, NSE
Share Holding Pre Issue	2,88,29,351 shares
Share Holding Post Issue	3,88,29,351 shares

Why a Fresh Issue Matters

Unlike many IPOs that include offer-for-sale components, Amanta Healthcare’s IPO is entirely a fresh issue. This means every rupee raised goes directly into the company’s growth plans rather than existing shareholders’ pockets, which is a positive sign for new investors.

Amanta Healthcare IPO GMP (September 2, 2025)

Current Grey Market Premium

As of September 2, 2025, 10:31 a.m., Amanta Healthcare’s Grey Market Premium (GMP) is ₹12. This means that, based on the top price band of 126, the anticipated listing price can be 138. Gains per share are projected to be 9.52%.

Financial Performance

Period Ended	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets (₹ cr.)	381.76	352.12	374.06
Total Income (₹ cr.)	276.09	281.61	262.70
Profit After Tax (₹ cr.)	10.50	3.63	-2.11
EBITDA (₹ cr.)	61.05	58.76	56.31
Net Worth (₹ cr.)	96.39	66.29	62.88
Reserves and Surplus (₹ cr.)	67.56	39.46	36.05
Total Borrowing (₹ cr.)	195.00	205.23	215.66

Business Segment Performance

Revenue Distribution:

• Domestic Branded Generics: 55% of total sales
• International Exports: 33% of revenue
• Partnerships & Contract Manufacturing: 10%

This diversified revenue mix provides stability and growth opportunities across different markets and product categories.

How Will Amanta Healthcare Use IPO Funds?

The company has outlined a clear roadmap for utilising the ₹126 crore raised:

Primary Allocation:

• ₹70 crores: Expanding SteriPort (ISBM) manufacturing capabilities for sterile pharmaceuticals
• ₹30.10 crores: Setting up new Small Volume Parenterals (SVP) production line
• Remaining funds: Working capital, general corporate purposes, and future growth initiatives

These investments directly support the company’s core manufacturing capabilities and should drive future revenue growth.

About Amanta Healthcare

Founded in 1994, Amanta Healthcare Limited has quietly built itself into one of the leading players in India’s pharmaceutical manufacturing landscape. Based in Ahmedabad, the company has spent three decades perfecting the art of sterile liquid formulations and medical device manufacturing.

What Sets Amanta Healthcare Apart?

Amanta Healthcare operates in some of the most critical segments of healthcare:

Core Product Portfolio:

• Sterile injectable solutions and IV fluids
• Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs)
• Ophthalmic solutions for eye care
• Respiratory care products and medical devices

Proprietary Technologies: The company leverages cutting-edge manufacturing processes including:

• ABFS (Aseptic Blow-Fill-Seal) technology for contamination-free production
• SteriPort (ISBM) systems for advanced sterile manufacturing

Global Footprint & Market Reach

Amanta Healthcare has successfully expanded beyond Indian borders, currently supplying products to 21 countries across Africa, Latin America, the UK, and other emerging markets. Domestically, the company works with over 320 distributors and stockists, ensuring widespread product availability.

Should You Invest in Amanta Healthcare IPO?

For Long-term Investors

The combination of specialised manufacturing capabilities, global reach, and improving profitability makes Amanta Healthcare attractive for investors with a 3-5 year investment horizon. The company’s focus on high-margin, sterile products and export growth provides a solid foundation for future expansion.

For Short-term Traders

The strong GMP and overwhelming subscription suggest potential listing gains. However, the premium valuation means any disappointment in market conditions could lead to volatility.

Risk Appetite Assessment

Conservative investors might want to wait for post-listing price discovery, while aggressive investors comfortable with pharmaceutical sector dynamics could consider participating.

Market Outlook for Pharmaceutical IPOs

The Indian pharmaceutical sector continues to benefit from several tailwinds:

Growth Drivers:

• Increasing healthcare spending and awareness
• Government initiatives supporting domestic manufacturing
• Growing export opportunities in regulated markets
• Rising demand for specialized formulations

Sector Challenges:

• Regulatory compliance costs
• Price pressure from government policies
• Competition from global pharmaceutical giants

Final Words

The Amanta Healthcare IPO presents an interesting opportunity to invest in a specialised pharmaceutical manufacturer with global ambitions. While the valuation appears full at current levels, the company’s niche focus, improving profitability, and expansion plans provide a compelling growth story.

However, investors should be mindful of the premium valuation and ensure it fits their portfolio strategy.